With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate

 
• By Joseph Haas
  
Ultragenyx hopes it and GeneTx have found right genomic approach to Angelman syndrome

More from Rare Diseases

More from Scrip